

29 June 2017

Resignation of Non-Executive Director

Resonance Health Ltd (ASX: RHT) advises that Non-Executive Director, Dr Jason Loveridge, has resigned from the Company, effective Friday 30th June 2017.

Following four years with the Company Dr Loveridge said; "It has been my pleasure to have served as a Director of Resonance Health for the past four years. The Company has come a long way over the past four years and it has a bright future, particularly with its entry into the AI space. I wish the Company and staff commercial success and a prosperous future."

Resonance Chairman, Dr Martin Blake commented; "The Board would like to thank Dr Loveridge for the contribution he has made to Resonance over the past four years. His decision to resign from the Board is due to his recent appointment as CEO of German biopharmaceutical company 4SC AG. Dr Loveridge will remain available to the company in a corporate advisory role."

We wish Dr Loveridge success with 4SC.

For further information please contact:

Sander Bangma

General Manager, Resonance Health

E: SanderB@resonancehealth.com P: +61 (0)8 9286 5300